科兴制药股价跌5.01%，华泰保兴基金旗下1只基金重仓，持有2.1万股浮亏损失4.47万元

Group 1 - The core viewpoint of the news is that Sinovac Biotech's stock has experienced a decline of 5.01%, with its current share price at 40.38 CNY and a total market capitalization of 8.127 billion CNY [1] - Sinovac Biotech, established on August 22, 1997, specializes in the research, production, and sales of recombinant protein drugs and micro-ecological preparations, with 97.38% of its revenue coming from pharmaceutical products [1] - The trading volume for Sinovac Biotech reached 194 million CNY, with a turnover rate of 2.30% [1] Group 2 - Huatai Baoxing Fund holds a significant position in Sinovac Biotech, with its Huatai Baoxing Kelong A fund (009124) owning 21,000 shares, representing 1.59% of the fund's net value, making it the eighth-largest holding [2] - The Huatai Baoxing Kelong A fund was established on May 11, 2020, and has a current scale of 20.8067 million CNY, with a year-to-date return of 9.58% and a one-year return of 14.97% [2] - The fund manager, Zhou Yongmei, has a tenure of 7 years and 213 days, with a best return of 43.67% during her management period [3]